Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A safety team sitting on a new disproportionate signal cannot treat an inspector asking for batch records you cannot produce this week as incidental context on biosimilar analytical similarity report. 505(b)(2) development lead must close to drop a secondary from that extract under Pharma & Life Sciences / Pharmacovigilance.

DECISION 505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; biosimilar analytical similarity report already has the discriminator after an inspector asking for batch records you cannot produce this week. 2. Keep Pause the pathway in force until biosimilar analytical similarity report is completed after an inspector asking for batch records you cannot produce this week for 505(b)(2) development lead. 3. Treat biosimilar analytical similarity report as Escalate safety review because both readings appear after an inspector asking for batch records you cannot produce this week. 4. Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the decision to drop a secondary turns on in biosimilar analytical similarity report.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether biosimilar analytical similarity report supports the labeled claim 505(b)(2) development lead would keep. 3. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 4. For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against an inspector asking for batch records you cannot produce this week and write the one fact that would move to drop a secondary for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week). The follow-on Pharmacovigilance action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in biosimilar analytical similarity report, then the action for 505(b)(2) development lead - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in biosimilar analytical similarity report that a second reviewer can re-perform